Q1 EPS Estimates for Cogent Biosciences Increased by Wedbush

Cogent Biosciences, Inc. (NASDAQ:COGT) – Equities researchers at Wedbush boosted their Q1 2025 earnings per share estimates for Cogent Biosciences in a research note issued to investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings per share of ($0.44) for the quarter, up from their previous estimate of ($0.47). Wedbush currently has a “Neutral” rating and a $11.00 target price on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.58) EPS, FY2026 earnings at ($1.32) EPS and FY2027 earnings at ($1.00) EPS.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. raised their price target on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reduced their target price on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a report on Wednesday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Cogent Biosciences Trading Down 4.0 %

Shares of Cogent Biosciences stock opened at $6.71 on Thursday. The firm has a market cap of $741.20 million, a P/E ratio of -2.71 and a beta of 1.77. Cogent Biosciences has a 12 month low of $5.73 and a 12 month high of $12.61. The stock’s fifty day moving average price is $8.19 and its 200-day moving average price is $9.56.

Hedge Funds Weigh In On Cogent Biosciences

Hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Cogent Biosciences by 38.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock valued at $43,000 after acquiring an additional 1,104 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Cogent Biosciences during the fourth quarter valued at about $78,000. Victory Capital Management Inc. acquired a new position in shares of Cogent Biosciences during the third quarter valued at about $113,000. Hsbc Holdings PLC acquired a new position in shares of Cogent Biosciences during the fourth quarter valued at about $81,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Cogent Biosciences during the fourth quarter valued at about $88,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.